Avid Bioservices Inc (CDMO)

[freethemice]

Three poster abstracts at ASCO confirmed. Only the titles until May 15th. Nothing for the first-line NSCLC trial.
http://iplanner.asco.org/am2013/am2013.aspx
Abstract #8095
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.
Mikhail Shtivelband, MD

Abstract #567
Phase I clinical trial of bavituximab (Bavi) and paclitaxel (P) in patients (pts) with HER2-negative metastatic breast cancer (MBC).
Pavani Chalasani, MD, MPH

Abstract #4054
Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.
Shuchi S. Pandya, MD